NRX Pharmaceuticals, Inc. · NASDAQ:NRXP

NRX Pharmaceuticals — Investor Presentation (September 2022)

29 slides from NRX Pharmaceuticals's investor presentation, September 2022

  1. Slide 1: Hope. Science. Life.

    Slide 1: Hope. Science. Life.

    Hope. NASDAQ: NRXP Science. Life. NRx Pharmaceuticals, Inc. Corporate Presentation Sept 2022 NASDAQ: NRXP

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation (this “Presentation”) is provided for informational purposes only. No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will NRx Pharmaceuticals, Inc.

  3. Slide 3: Our Mission: We Bring Hope to Life

    Slide 3: Our Mission: We Bring Hope to Life

    OUR MISSION We Bring Hope to Life Life-saving Medicines For People With Unmet Medical Needs Our medicines are based on newly-addressable molecular targets for illnesses that are not targeted by major pharmaceutical companies. 3

  4. Slide 4: Leading the Way: Our Focus on Brain Health

    Slide 4: Leading the Way: Our Focus on Brain Health

    LEADING THE WAY: OUR FOCUS ON BRAIN HEALTH There are no medicines today for people with suicidal bipolar depression. Someone attempts suicide every second, somewhere in the world, every 27 seconds in the US. Current antidepressants do not decrease suicidal ideation and are known to increase the risk

  5. Slide 5: Leadership Team

    Slide 5: Leadership Team

    Leadership Team Stephen Willard, JD – CEO & Director 30+ years of management of publicly traded biotechnology companies, with a strong background in law and finance. Served in CEO roles such as Cellphire Therapeutics, and Flamel Technologies, now Avadel Pharmaceuticals and has held leadership and di

  6. Slide 6: Experienced Board of Directors

    Slide 6: Experienced Board of Directors

    EXPERIENCED BOARD OF DIRECTORS Drug development, health policy, biosecurity 30 years senior executive experience Patrick Flynn, MBA CEO Health Dialog – exit to BUPA International Chair, Audit & Compensation Committees Bank of America (15 years), VP World Banking and Risk Management BS Finance, Whart

  7. Slide 7: NRx R&D Pipeline: Multi-Billion Dollar Potential in Psychiatry

    Slide 7: NRx R&D Pipeline: Multi-Billion Dollar Potential in Psychiatry

    NRx R&D Pipeline: Multi-Billion Dollar Potential in Psychiatry Indication Compound Pre clinical Phase 1 Phase 2 Phase 3 Marketed Bipolar Depression & Suicidal Ideation Severe Bipolar Depression with Data readout expected NRX-100™ / NRX-101™ FDA SPA, Breakthrough, Biomarker letter of Support Acute Su

  8. Slide 8: NRX-101

    Slide 8: NRX-101

    NRX-101™ The first oral, non-hallucinogenic, non-addictive medicine in development to treat Bipolar Depression in Patients with Acute suicidality* and Subacute suicidality** *ASIB - requiring hospitalization **SSIB – not requiring hospitalization

  9. Slide 9: Why Target Suicidal Bipolar Depression

    Slide 9: Why Target Suicidal Bipolar Depression

    Why Target Suicidal Bipolar Depression Suicide kills ~50,000 Americans annually - Suicide is particularly high in bipolar disorder If you know two people with bipolar depression, one will attempt suicide, If you know five people with bipolar depression, one will succeed. 9

  10. Slide 10: Suicidal Bipolar Depression: The Only Approved Treatment is ECT

    Slide 10: Suicidal Bipolar Depression: The Only Approved Treatment is ECT

    Suicidal Bipolar Depression: The Only Approved Treatment is ECT No Approved Medicine No Good Choices Antidepressants (SSRIs) can increase suicidality Patients with suicidality are routinely excluded from clinical trials of other antidepressants Ketamine provides strong proof of concept but is known

  11. Slide 11: Suicidal Bipolar Depression: The Unmet Need

    Slide 11: Suicidal Bipolar Depression: The Unmet Need

    Suicidal Bipolar Depression: The Unmet Need There is no approved drug for Suicidal Bipolar Depression. There are 100+ drugs for Major Depressive Disorder and, only a few for Bipolar Depression, and they all carry a Suicide Warning on the label. Drugs for Major Depressive Disorder (MDD) Drugs for Bip

  12. Slide 12: Understanding the NMDA Receptor

    Slide 12: Understanding the NMDA Receptor

    Understanding the NMDA Receptor NRX-100 / NRX-101 to treat Bipolar Depression with Acute Suicidality. NRx-101 NMDA receptor antagonists have been known to have antidepressant effects for many years. Their use has been limited by potential for addiction, hallucination and Neurotoxicity. Recent eviden

  13. Slide 13: Simultaneous Blockade of NMDA and 5-HT2A Blocks NMDA Side Effects

    Slide 13: Simultaneous Blockade of NMDA and 5-HT2A Blocks NMDA Side Effects

    The Patented NRx Discovery: 90 patents around the world Simultaneous Blockade of NMDA and 5-HT2A Blocks NMDA Side Effects DCS (D-Cycloserine) Lurasidone blocks side-effects of 5HT2A Blocks side-effects of NMDA Psychosis Akathisia 13

  14. Slide 14: NRX-101 Market Opportunity in Bipolar Depression with Suicidality

    Slide 14: NRX-101 Market Opportunity in Bipolar Depression with Suicidality

    NRX-101 Market Opportunity Patients in Clinics and outpatient being treated for Bipolar Depression with in Bipolar Depression with Suicidality Suicidality FDA has granted Breakthrough Therapy Designation, a Special Protocol Agreement, and Biomarker Letter of Support for treatment US Bipolar Populati

  15. Slide 15: NRX-101 Market Opportunity in Bipolar Depression

    Slide 15: NRX-101 Market Opportunity in Bipolar Depression

    NRX-101 Market Opportunity in Bipolar Depression Patient Opportunity Patients in clinics and outpatient being treated for Bipolar Depression with Suicidality Adults With Bipolar 7,000,000 9-10% Patients With Suicidality 680,000 26% 74% $2.2 Billion ACUTE 180,000 Subacute Suicidality 500,000 Market P

  16. Slide 16: Phase 2 Study Showed Effect of D-Cycloserine in Depression/Suicidality

    Slide 16: Phase 2 Study Showed Effect of D-Cycloserine in Depression/Suicidality

    Phase 2 Study showed effect of D-Cyclosrine in Depression/Suicidality If Phase 2 results are replicated in Phase 3, this will meet criteria for FDA approval. Mean 7.7 point benefit on MADRS (Primary Endpoint, P=.03) through day 42 vs. lurasidone. This difference is similar to or larger than that see

  17. Slide 17: The STABIL-B Findings Are Supported by Independent Studies

    Slide 17: The STABIL-B Findings Are Supported by Independent Studies

    The STABIL-B findings Are Supported by 3 Independent Studies A series of smaller studies have shown an improved antidepressant and anti-suicidal effect of DCS when added to 5HT2A / SSRIs Heresco-Levy et. al.(1) Kantrowitz et. al.(2) Chen et. al.(3) Treatment Resistant Depression Treatment Resistant

  18. Slide 18: Expedited Approval Path through FDA

    Slide 18: Expedited Approval Path through FDA

    Expedited Approval Path through FDA FDA Reviewed the STABIL-B data and awarded Breakthrough Therapy Designation (BTD) together with a Special Protocol Agreement (SPA) The SPA letter signed by FDA allows NRx to apply for drug approval with a successful phase 3 trial of ~70 Patients using similar meth

  19. Slide 19: Phase 2 Trial in Subacute Suicidality

    Slide 19: Phase 2 Trial in Subacute Suicidality

    Phase 2 Trial in Subacute Suicidality Targeting patients who are cared for in the outpatient setting, but are at risk for hospitalization (C-SSRS 3/4) Enrollment underway at ~ 10 study sites in the United States 19

  20. Slide 20: Extending Findings of STABIL-B to Subacute Suicidality in Bipolar

    Slide 20: Extending Findings of STABIL-B to Subacute Suicidality in Bipolar

    Extending findings of STABIL-B to Subacute Suicidality in Bipolar Patients being seen in psychiatrists’ offices who do not yet need hospitalization Phase 2 trial of NRX-101 vs. Lurasidone without prior ketamine for stabilization. Patients with MADRS ≥ 30 (severe depression) and C-SSRS 3 or 4 (subacu

  21. Slide 21: Magnetic Resonance Spectroscopy Supports Mechanism of Action

    Slide 21: Magnetic Resonance Spectroscopy Supports Mechanism of Action

    Magnetic Resonance Spectroscopy Supports Mechanism of Action NMDA antagonists, by stimulating brain glutamate are now known from nonclinical studies to “rewire” the brain by stimulating new connections between brain cells in the frontal cortex NRx is the only company in the psychiatry field to have

  22. Slide 22: Path to Commercialization by 2024

    Slide 22: Path to Commercialization by 2024

    Path to Commercialization by 2024 Technology and Manufacturing Transfer to USA completed in Q2 2022 Expecting to release first Phase 3/Commercial Scale drug in October 2022 Potential for Commercial Sales of NRX-101 by 2024 Options for either Direct Launch or license/partnering 22

  23. Slide 23: NRx has Composition of Matter Patent Protection

    Slide 23: NRx has Composition of Matter Patent Protection

    NRx has Composition of Matter Patent Protection Patent Estate of 47 issued and 43 pending patents enables a platform of CNS drugs based on NMDA / 5HT2A Synergy. Five patent families, 90+ filed applications, 47 issued patents in US/EU/CN/JP/KO/AU. Protects NRX-101 to at least 2033 with potential for

  24. Slide 24: NRX-101 for PTSD

    Slide 24: NRX-101 for PTSD

    NRX-101™ for PTSD Post-9/11, we have lost 4x more veterans and servicemembers to suicide than combat. No approved medicine for PTSD symptoms Only approved Medicine for PTSD-related Depression are SSRI’s that carry black box suicide warnings and do not affect Fear Memory

  25. Slide 25: PTSD With and Without Suicidality

    Slide 25: PTSD With and Without Suicidality

    PTSD With and Without Suicidality Unmet Need 9+ Million 10% Have Suicidality EFFICACY • Higher % responders • Faster Onset SAFETY/ TOLERABILITY 1/3 With Severe >30K Veteran Deaths $5+ Billion Market Potential • Decrease or no increase in Suicidality Since 9/11 PTSD • Lower Side Effects Sources: Nati

  26. Slide 26: Preclinical Support for NRX-101 in PTSD

    Slide 26: Preclinical Support for NRX-101 in PTSD

    Preclinical Support for NRX-101 in PTSD DCS-induced Reduced Fear Memory in WKY Rodent model of PTSD Depression in PTSD may be driven by pathways that are similar to those that drive depression in other conditions (NMDA and 5-HT2A. PTSD is unique in that “Fear Memory” with recurring images of traumat

  27. Slide 27: Financials & Summary

    Slide 27: Financials & Summary

    Financials & Summary We apply innovative science to known molecules to develop life-saving medicines.

  28. Slide 28: Financial Position

    Slide 28: Financial Position

    Financial Position NRXP Publicly traded Total Shares on NASDAQ NRxNRx Cash Cash Total Shares Outstanding: Position: Position: Outstanding: following SPAC merger $24.5 million ~67 million $24.5 million as ~67 million completed in as of 6/30/2022 shares as of of 6/30/2022 shares as of May 2021 8/1/202

  29. Slide 29: Hope. Science. Life.

    Slide 29: Hope. Science. Life.

    Hope. NASDAQ: NRXP Science. Life. NRx Pharmaceuticals, Inc. Corporate Presentation Sept 2022

Source: Internet Archive copy of nrxpharma.com

More decks from NRX Pharmaceuticals, Inc.

All 10 NRX Pharmaceuticals decks